molecules of the month


selective, reversible LSD1 inhibitor

<100 mg orally QW, in Ph. II for 1L ES-SCLC

from 300k+ cmpd HTS, SBDD + opt.

J. Med. Chem., Oct. 9, 2020

Celgene/Bristol Myers Squibb, San Diego, CA

Structure of CC-90011
1 min read

CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: